Within the United States, cord blood banks are subject to federal and state regulations and all cord blood banks must be registered with the U.S. FDA. The FDA governs all aspects of cord blood preservation, including the collection, processing, storage, labeling, packaging, and distribution of cord blood stem cells. In addition, there are a number of other agencies that accredit cord blood banks, including the AABB, Foundation for the Accreditation of Cellular Therapy (FACT), Clinical Laboratory Improvement Amendments (CLIA), and more.
[Read more…]
BioInformant iPS Cell Data Featured on Centre for Commercialization of Regenerative Medicine
BioInformant is excited to share that our induced pluripotent stem cell industry analytics have been featured on the “Signals Blog,” published by the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies.
The post, titled Right Turn: Commercializing iPSCs – Infographics, states:  “The beauty of an infographic (or two) is it speaks for itself.”
View Full CCRM Post Â
If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]
Hematopoietic Stem Cell Transplant Rates, Utilization of Cord Blood, Awareness Rates, and More
The cord blood banking market has emerged gradually over the past 40 years, as 1974 was the first year in which it was proposed that stem and progenitor cells were present in human cord blood.[1]  In the forthcoming years it was established that cord blood stem cells had similar properties as bone marrow and could be used as an alternative.  Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell based therapy, both for the treatment of hematological and non-hematological disorders.
[Read more…]
Induced Pluripotent Stem Cell (iPSC) News Round-Up| February 2015
“Supreme Court Rules on Stem Cells, $100 Billion Proposed for International Stem Cell Collaboration, Japan to Launch iPSC Therapy Center, and More”
Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015. [Read more…]
Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015
The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]